Nasdaq: Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI
Transaction is part of wide-ranging collaboration to combine Quest's oncology expertise and scale with PathAI's AI and digital pathology innovations to speed diagnosis, improve quality and reduce ...
Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI
Quest Diagnostics (DGX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook ...
QUEST DIAGNOSTICS ($DGX) posted quarterly earnings results on Tuesday, April 22nd. The company reported earnings of $2.21 per share, beating estimates of $2.17 by $0. ...
Shares of Quest Diagnostics (NYSE:DGX) rose on Tuesday after the company reported Q2 results above expectations, and raised its full year guidance. Quest reported second quarter revenue of $2.76B, ...
Morningstar: Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on
Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on
Zacks Investment Research on MSN: Quest Diagnostics (DGX) reports next week: Wall Street expects earnings growth
Quest Diagnostics (NYSE:DGX) reported a strong quarterly performance supported by increased testing volumes and service expansion. The company processes a significant portion of laboratory tests ...
Quest Diagnostics Incorporated has seen modest growth in recent years, although serial buybacks have increased growth on a per-share basis to attractive percentages. The company has been resilient and ...